Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10284796" target="_blank" >RIV/00216208:11110/14:10284796 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/14:10284796

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.vaccine.2013.11.049" target="_blank" >http://dx.doi.org/10.1016/j.vaccine.2013.11.049</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.vaccine.2013.11.049" target="_blank" >10.1016/j.vaccine.2013.11.049</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths

Popis výsledku v původním jazyce

Background: Human papillomavirus (HPV) vaccination offers potential for primary prevention of HPV-related pre-cancers and cancers as demonstrated in clinical trials. Mathematical models have estimated the potential real-life impact of vaccination on theburden of cervical cancer (CC). However, these are restricted to evaluations in a limited number of countries. Methods: Potential decline in CC cases and deaths with the AS04-adjuvanted HPV-16/18 vaccine of young girls naive to HPV, was estimated at steady-state (vaccine coverage: 0-100%) based on clinical trial and country-specific incidence data. Data on vaccine efficacy were taken from the end of study PATRICIA trial of the AS04-adjuvanted HPV-16/18 vaccine. The numbers of cases and deaths due to HPV-16/18 were estimated and compared with those due to any HPV type to estimate the additional cases prevented. This difference estimates CC cases and deaths avoided due to protection against non-vaccine HPV types. Cost-offsets due to reduc

Název v anglickém jazyce

Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths

Popis výsledku anglicky

Background: Human papillomavirus (HPV) vaccination offers potential for primary prevention of HPV-related pre-cancers and cancers as demonstrated in clinical trials. Mathematical models have estimated the potential real-life impact of vaccination on theburden of cervical cancer (CC). However, these are restricted to evaluations in a limited number of countries. Methods: Potential decline in CC cases and deaths with the AS04-adjuvanted HPV-16/18 vaccine of young girls naive to HPV, was estimated at steady-state (vaccine coverage: 0-100%) based on clinical trial and country-specific incidence data. Data on vaccine efficacy were taken from the end of study PATRICIA trial of the AS04-adjuvanted HPV-16/18 vaccine. The numbers of cases and deaths due to HPV-16/18 were estimated and compared with those due to any HPV type to estimate the additional cases prevented. This difference estimates CC cases and deaths avoided due to protection against non-vaccine HPV types. Cost-offsets due to reduc

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FK - Gynekologie a porodnictví

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Vaccine

ISSN

0264-410X

e-ISSN

—

Svazek periodika

32

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

733-739

Kód UT WoS článku

000331501900015

EID výsledku v databázi Scopus

—